Clinical trial
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced…
NCT00347919 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00347919 |
|---|---|
| Title | Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer |
| Official title | A Phase II, Open-Label, Randomized, Multicenter Trial of GW786034 (Pazopanib) in Combination With Lapatinib (GW572016) Compared to Lapatinib Alone as First Line Therapy in Subjects With Advanced or Metastatic Breast Cancer With ErbB2 Fluorescence In Situ Hybridization (FISH) Positive Tumors |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neoplasms, Breast |
| Intervention type | Drug |
| Interventions | pazopanib (GW786034) 400 mg, lapatinib (GW572016) 1500 mg, lapatinib (GW572016) 1000 mg, pazopanib (GW786034) 800 mg |
| Enrollment | 189 |
| Start date | Jul 1, 2006 |
| Primary completion | Aug 1, 2008 |
| Completion | Mar 1, 2015 |
| First posted | Jul 4, 2006 |
| Last update posted | Feb 25, 2016 |
| Countries | Canada, France, Hungary, India, Israel, Malaysia, Mexico, Pakistan, Peru, Poland, Russia, Singapore and 4 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: